Development and Immunogenicity of a Prototype Multivalent Group B Streptococcus Bioconjugate Vaccine

[Image: see text] Group B Streptococcus (GBS) is a leading cause of neonatal infections and invasive diseases in nonpregnant adults worldwide. Developing a protective conjugate vaccine targeting the capsule of GBS has been pursued for more than 30 years; however, it has yet to yield a licensed produ...

Descripción completa

Detalles Bibliográficos
Autores principales: Duke, Jeremy A., Paschall, Amy V., Robinson, Lloyd S., Knoot, Cory J., Vinogradov, Evgeny, Scott, Nichollas E., Feldman, Mario F., Avci, Fikri Y., Harding, Christian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793035/
https://www.ncbi.nlm.nih.gov/pubmed/34633812
http://dx.doi.org/10.1021/acsinfecdis.1c00415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793035/
https://www.ncbi.nlm.nih.gov/pubmed/34633812
http://dx.doi.org/10.1021/acsinfecdis.1c00415

Ejemplares similares